GlassScriptPhysician profile
Theodore R Brown
NPI 1568416873
$61,764.47
in general payments reported to CMS, 2019-2025
48 companies · $1,689 in 2025
The $1,689 reported for 2025 was more than what 92% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $8,436 · 2021: $7,021 · 2022: $15K · 2023: $1,065 · 2024: $7,227 · 2025: $1,689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,404 · Food and Beverage: $4,270 · Travel and Lodging: $240 · Education: $65.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,404.00 |
| Food and Beverage | $4,270.47 |
| Travel and Lodging | $240.41 |
| Education | $65.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $12,865.37 | 2020-2022 | |
| Celgene Corporation | $11,929.13 | 2020-2025 | Zeposia |
| Genzyme Corporation | $9,051.01 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $7,949.05 | 2019-2025 | |
| Merck Kgaa | $7,013.50 | 2019 | |
| Greenwich Biosciences, INC. | $6,590.04 | 2019 | |
| Emd Serono, INC. | $1,964.39 | 2019-2025 | Mavenclad |
| Tg Therapeutics, INC. | $1,046.89 | 2023-2025 | |
| Abbvie INC. | $607.15 | 2021-2025 | Botox, Ubrelvy |
| Merz Pharmaceuticals, LLC | $533.82 | 2021-2025 | Xeomin, Inbrija, Ampyra |
| Teva Pharmaceuticals USA, INC. | $224.41 | 2019-2025 | Austedo Xr, Austedo Xr |
| Acorda Therapeutics, INC | $172.65 | 2020-2023 | Inbrija, Ampyra |
| Ucb, INC. | $167.85 | 2020-2025 | Fintepla, Nayzilam, Briviact |
| Genentech USA, INC. | $122.72 | 2021-2025 | Ocrevus |
| Biogen, INC. | $116.00 | 2022 |
Show all 45 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.